SRGN and neoplasm: We previously reported that a proteoglycan serglycin (SRGN) is overexpressed in esophageal carcinoma 12 and in highly invasive esophageal squamous cell carcinoma (ESCC) cells lines 13, and that SRGN and its binding partners have autocrine and paracrine tumor-promoting functions in the TME 12, 14.